



**Questions and answers on the referral for
Sabumalin
salbutamol, metered dose aerosol inhaler, 100 µg/dose**

The European Medicines Agency (EMA) has completed a referral procedure following a disagreement among Member States of the European Union regarding the authorisation of the medicine Sabumalin. The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Sabumalin outweigh its risks, and that the marketing authorisation can be granted in Sweden as well as in the following Member States of the European Union: Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Slovenia, Spain and the United Kingdom. The review was carried out under an 'Article 29' referral¹.

What is Sabumalin?

Sabumalin is a medicine in a pressurised inhaler that contains salbutamol as active substance. Salbutamol is a beta2-adrenergic receptor agonist. This means that salbutamol activates the beta2-receptors in the body. When given by inhalation as in Sabumalin, salbutamol directly activates the beta2-receptors in the respiratory system. This makes the airways widen, allowing the air to flow more freely.

Sabumalin is used to treat the breathing difficulties caused by asthma and chronic obstructive pulmonary disease (COPD). It can also be used to prevent asthma symptoms caused by exercise or other triggering factors, such as house dust, pollen, cats, dogs and cigarette smoke. Sabumalin is used to relieve symptoms, and its use should not delay the use of inhaled steroids.

Sabumalin is a 'generic medicine'. This means that Sabumalin is similar to a 'reference medicine' already authorised in the European Union (EU) called Sultanol inhaler.

Why was Sabumalin reviewed?

Hexal AG submitted Sabumalin to the Swedish medicines regulatory agency for a decentralised procedure on 5 December 2006. This is a procedure when one Member State (the 'reference Member State', in this instance Sweden) assesses a medicine with a view of granting a marketing authorisation that will be valid in this country as well as in other member states (the 'concerned Member States', in this instance Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Slovenia, Spain and the United Kingdom). These member states were not able to reach an agreement. On 4 March 2008, the Swedish medicines regulatory agency referred the matter to the CHMP.

The grounds for the referral were concerns regarding that there was not enough data showing that Sabumalin is equivalent to the reference medicine. Concerns were also raised regarding how to store the inhaler and the effect of the orientation of the inhaler on the delivery of the medicine.

What are the conclusions of the CHMP?

Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Sabumalin outweigh its risks, and that therefore the marketing authorisation for Sabumalin should be granted in all concerned member states.

¹ Article 29 of Directive 2001/83/EC as amended, referral on the grounds of potential serious risk to public health

The European Commission issued a decision on 12 March 2009.

Rapporteur:	Prof Michal Pirożynski (Poland)
Co-rapporteur:	Dr Gonzalo Calvo Rojas (Spain)
Referral start date:	19 March 2008
Company responses provided on:	30 May 2008, 20 October 2008
Opinion date:	18 December 2008